News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IBRX This company is a game changer, and for investors, potentially a life changer. IMHO, this is true:
* Unrivaled vision targeting indications worth hundreds of billions.
* Multiple platforms synchronized to provide symbiotic pathways and a multi-faceted approach to both treatment and cures.
* People, patents, mfg plants on a scale typically seen only with big pharma
* Vision, scope, and claims backed up by stellar trial results that exceed SOC (including Keytruda).
* Potential for SOC, first line treatment, and preventative care ranging from cancer to covid (icing on an already huge cake)
* A billionaire backer with a proven track record who is unlikely to quit or sell.
14,072,615 Shares of Common Stock
Warrants to Purchase up to 14,072,615 Shares of Common Stock
and
the Shares of Common Stock underlying the Warrants
We are offering 14,072,615 shares of our common stock, par value $0.0001 per share (the “common stock”), and warrants to purchase up to 14,072,615 shares of our common stock (and the shares of common stock issuable from time to time upon exercise of those warrants). Each share of common stock sold in this offering will be accompanied by a warrant to purchase one share of our common stock at an exercise price of $4.2636 per share. Each share of common stock and the accompanying warrant is being sold at a combined offering price of $3.5530. Subject to certain ownership limitations, the warrants will be immediately exercisable, and the warrants will expire two years after the initial issuance date. The shares of common stock and the warrants will be issued separately. We refer to the shares of common stock and the accompanying warrants, including the underlying shares of common stock, to be issued in this offering, collectively, as the “securities.”
2022 Top Story in Bladder Cancer: Use of N-803 With BCG in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
The final results from an open-label multicenter study (NCT03022825) examining the use of N-803 with BCG in patients with BCG-unresponsive non–muscle invasive bladder cancer were presented at ASCO in June and published in the Journal of Clinical Oncology.1
N-803, an IL-15 super agonist that activates natural killer cells and CD8+ T cells, was combined with BCG and tested in patients in two cohorts: group A (carcinoma in situ [CIS]) and group B (papillary disease).
A total of 160 patients (83 with CIS and 77 with papillary disease) were enrolled, and the median number of prior BCG doses was 12. Patients received intravesical N-803 with BCG using standard induction and maintenance dosing.
The authors reported results for each cohort. Among patients with CIS, 71% (59/83) had a complete response, with a median duration of 24 months in responders. There was a 96% 2-year bladder cancer–specific progression-free survival in muscle-invasive bladder cancer. For patients with papillary disease, 12-month and 24-month disease-free survival rates of 57% and 48% were noted. At 2 years of follow-up, a total of 90% had avoided cystectomy.
Treatment was well-tolerated. Low-grade treatment-related adverse events were reported, including dysuria (22%) and urgency (12%), and there were no grade 4 or 5 adverse events. No immune-related serious adverse events occurred.
In summary, for patients with BCG-unresponsive disease, N-803 plus BCG offers a safe, effective, and well-tolerated treatment option.
This study is significant because treating BCG-unresponsive disease is challenging and patients have limited options. Also, many patients may not be eligible for or wish to undergo cystectomy. This important study offers a new option that can provide a durable treatment alternative for patients with a life-threatening bladder cancer diagnosis.
|
Followers
|
61
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1643
|
|
Created
|
07/26/15
|
Type
|
Free
|
| Moderators | |||
| Shs Outstand | 98.47M |
| Shs Float | 28.16M |
| Debt/Eq | 0.00 |
| LT Debt/Eq | 0.00 |
| Employees | 153 |
AI
